AC Immune (NASDAQ:ACIU) Shares Gap Down to $7.62

AC Immune SA (NASDAQ:ACIU) shares gapped down before the market opened on Tuesday . The stock had previously closed at $7.62, but opened at $7.45. AC Immune shares last traded at $7.37, with a volume of 500 shares.

Several analysts have recently issued reports on ACIU shares. HC Wainwright upped their price target on AC Immune from $11.00 to $16.00 and gave the stock a “buy” rating in a research note on Tuesday, March 30th. Zacks Investment Research raised AC Immune from a “sell” rating to a “hold” rating in a research report on Tuesday, January 26th.

The firm has a fifty day simple moving average of $7.74 and a 200 day simple moving average of $6.12. The stock has a market cap of $504.28 million, a price-to-earnings ratio of -7.79 and a beta of 0.82.

Several institutional investors and hedge funds have recently modified their holdings of the company. Squarepoint Ops LLC acquired a new position in shares of AC Immune in the 4th quarter worth approximately $255,000. Engineers Gate Manager LP acquired a new position in shares of AC Immune in the 4th quarter worth approximately $63,000. Wells Fargo & Company MN raised its holdings in shares of AC Immune by 55.5% in the 4th quarter. Wells Fargo & Company MN now owns 323,454 shares of the company’s stock worth $1,672,000 after buying an additional 115,509 shares in the last quarter. Banque Cantonale Vaudoise grew its position in AC Immune by 4.5% during the 4th quarter. Banque Cantonale Vaudoise now owns 58,285 shares of the company’s stock worth $303,000 after acquiring an additional 2,516 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in AC Immune during the 3rd quarter worth approximately $159,000. 27.68% of the stock is owned by institutional investors and hedge funds.

About AC Immune (NASDAQ:ACIU)

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

See Also: Cost of Debt

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.